AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EUDA Health shares surge 10.8% premarket after executing Securities Purchase Agreement for capital raise.
ByAinvest
Friday, Dec 12, 2025 4:03 am ET1min read
EUDA Health Holdings Limited surged 10.80% in premarket trading following the announcement that its subsidiary, CK Health Plus, expanded into India through a strategic partnership with SafeRock India. The collaboration aims to leverage EUDA’s longevity and wellness expertise in the Indian market, a key growth opportunity. Additionally, CK Health Plus recently secured a direct selling license in Malaysia, further solidifying EUDA’s regional expansion in Asia. These developments, coupled with ongoing advancements in stem cell therapy and immune health products, signaled strong growth potential to investors, driving the premarket rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet